1. Scrip
  2. >>Business

Abingworth Closes 12th Life Sciences Fund ABV VII At $315M

 
• By Mike Ward
  
Generate a summary of this article
Listen to this article
Beta

European biotechs are likely to be the big winner as transatlantic VC Abingworth closes its latest fund, Abingworth Ventures VII (ABV VII), at $315m, exceeding its $300m target.

With a number of high-profile exits under its belt, Abingworth has been able to expand its own investor base and raise $315m for ABV VII. The new vehicle is the VC’s 12th fund and means that Abingworth now has more than $1.2bn under management. And while the transatlantic VC will still focus on all stages of US and European life science companies, subtle shifts in focus are expected for ABV VII.

While Abingworth has been a pioneer of a balanced portfolio, investing in both early and late stage, clinical co-development opportunities,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip